Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06982183 · ClinicalTrials.gov registry record · Phase 4

The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes

A Phase 4 study of Acute Stress Reaction and Fear of Spiders, sponsored by Walter Reed Army Institute of Research (WRAIR).

Recruiting
Registry status
Phase 4
Development phase
110
Enrollment target
1
Study location

NCT06982183: Recruiting Phase 4 study of Acute Stress Reaction and Fear of Spiders, sponsored by Walter Reed Army Institute of Research (WRAIR).

NCT06982183 is a Phase 4 study of Acute Stress Reaction and Fear of Spiders that is actively recruiting participants, run by Walter Reed Army Institute of Research (WRAIR). The registered enrollment target is 110 participants, below the 252-participant average among 3 other Acute Stress Reaction trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06982183, a Phase 4 study of Acute Stress Reaction and Fear of Spiders, is actively recruiting participants, sponsored by Walter Reed Army Institute of Research (WRAIR).

RECRUITING
Registry status
Phase 4
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

This clinical trial aims to evaluate the nature and duration of effects of three FDA-approved medications (propranolol, hydrocortisone, and morphine) on military-relevant cognitive, emotional, and motor performance following an exposure to a stressful situation (i.e., exposure to a tarantula) in physically healthy adult volunteers (aged 18 - 40) with fear of spiders to help the future development of medications for treating Acute Stress Reactions. The main questions this study aims to answer are: Will placebo treatment (oral placebo) result in significant decrements in Psychomotor Vigilance Task (PVT) performance compared to propranolol treatment? Will placebo treatment \[intramuscular (IM) placebo\] result in significant decrements in PVT performance compared to hydrocortisone treatment? Will placebo treatment (IM placebo) result in significant decrements in PVT performance compared to morphine treatment? Participants will receive one of five study medications (oral propranolol, oral placebo, IM hydrocortisone, IM morphine, or IM morphine) after a brief exposure to a tarantula. Participants will complete cognitive and simple motor tasks and psychological assessments before and after the study medication administration.

Primary Outcome

Measure of cognitive performance. Reaction time (millisecond)

Conditions Studied

Acute Stress Reaction Fear of Spiders

Interventions

  • DRUG Hydrocortisone
  • DRUG Propranolol
  • DRUG Morphine
  • DRUG Placebo (oral)
  • DRUG Placebo (IM)

Study Locations (1)

Maryland

  • Sleep Research Center (SRC), Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2025-05-27
Est. Completion 2026-09
Phase Phase 4
Walter Reed Army Institute of Research (WRAIR)

12 total trials

What NCT06982183 shows while recruiting

NCT06982183 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 252-participant average among 3 other Acute Stress Reaction trials with a reported enrollment target (56% lower).

The record links to 2 conditions, with Acute Stress Reaction appearing as the primary indexed condition, and to 5 interventions - of which Hydrocortisone is the first listed.

NCT06982183 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06982183 about?

NCT06982183 is a clinical study titled "The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes". This clinical trial aims to evaluate the nature and duration of effects of three FDA-approved medications (propranolol, hydrocortisone, and morphine) on military-relevant cognitive, emotional, and motor performance following an exposure to a stressful situation (i.e., exposure to a tarantula) in phy...

What is the current status of trial NCT06982183?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2025-05-27. Estimated completion is 2026-09.

What conditions does trial NCT06982183 study?

This clinical trial studies the following conditions: Acute Stress Reaction, Fear of Spiders.

What interventions are being tested in trial NCT06982183?

The interventions under investigation include: Hydrocortisone (DRUG), Propranolol (DRUG), Morphine (DRUG), Placebo (oral) (DRUG), Placebo (IM) (DRUG).

Who is sponsoring clinical trial NCT06982183?

This trial is sponsored by Walter Reed Army Institute of Research (WRAIR), which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06982183 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Stress Reaction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06982183

Source: ClinicalTrials.gov NCT06982183, the US trial registry maintained by the National Library of Medicine. NCT06982183 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.